Introduction
Mordor Intelligence, in its latest anti‑obesity drugs market report, forecasts the market to reach from USD 25.93 billion in 2025 to USD 100.97 billion by 2030, advancing at a 31.24 % CAGR. The anti-obesity drugs market focuses on medications developed to aid in weight loss and manage obesity related conditions. Obesity is a chronic, relapsing condition associated with several health issues, including type 2 diabetes, cardiovascular diseases, sleep apnea, and certain cancers. As global obesity rates rise driven by sedentary lifestyles, poor dietary habits, and genetic factors, there is growing demand for medical interventions beyond lifestyle changes and bariatric surgery.
Key Trends
The anti‑obesity drugs landscape is being reshaped by several important developments:
1. GLP‑1 receptor agonists gaining dominance Gut‑hormone incretins, primarily GLP‑1 agonists, are set to expand at 33.15 % CAGR through 2030. Their strong efficacy in reducing weight and favorable safety profiles have led major pharmaceutical companies to scale up production and secure lifecycle extensions for these agents
2. Oral formulations on the rise Although injectables account for 81.3 % of the 2024 market share, oral anti‑obesity drugs are projected to grow at an impressive 36.6 % CAGR through 2030. This surge reflects patient preference for pill-based therapies and investment in oral GLP‑1 pills by developers.
3. Prescription segment maintains leadership Prescription drugs commanded 84.2 % of the anti‑obesity drugs market in 2024. Over‑the‑counter options trail behind but are gaining traction, with the prescription category still growing at a 32.56 % CAGR through 2030
4. Digital pharmacies unlocking access Retail pharmacies held 54.05 % of the market in 2024, but online pharmacies are catching up. They are expected to grow at a 34.75 % CAGR, spurred by e‑commerce ease and expanding reimbursement support.
5. Asia‑Pacific emerging fast North America remains the largest market with a 65.9 % revenue share in 2024. However, Asia‑Pacific is advancing at a robust 33.65 % CAGR, driven by rising healthcare spending and expanding obesity awareness.
Market Segmentation
The anti‑obesity drugs market can be segmented in multiple ways, enabling stakeholders to identify growth pockets and tailor strategies.
By Mechanism of Action
Peripherally acting drugs led revenue in 2024, capturing 60.10% of the market. These medications act within the digestive system, such as fat‑absorption inhibitors and appetite suppressants, reducing energy uptake or signalling fullness.
Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through 2030. These therapies mimic or enhance gut hormones to regulate appetite and blood sugar.
By Drug Type
Prescription drugs held a dominant share at 84.20% in 2024. This category includes clinically validated medications with regulatory backing and reimbursement frameworks.
Over‑the‑counter (OTC) drugs occupy a smaller share but are gradually gaining influence through ease of access and increasing consumer trust.
By Route of Administration
Injectables commanded 81.30% of the market in 2024, driven by the widespread use of injectable GLP‑1 therapies known for their strong efficacy.
Oral drugs are emerging as the most dynamic segment, projected to grow at a 36.60% CAGR from 2025 to 2030, reflecting a clear patient trend toward pills over injections.
By Distribution Channel
Retail pharmacies made up 54.05% of market revenues in 2024, remaining the standard way for patients to obtain anti‑obesity medications.
Online pharmacies are fast growing (projected 34.75% CAGR to 2030), propelled by telehealth, convenient home delivery, and evolving reimbursement policies.
By Geography
North America was the largest regional market, securing a 65.90% share in 2024. This dominance stems from advanced healthcare systems, approval frameworks, and strong payer support.
Asia‑Pacific is the fastest expanding region, with a projected CAGR of 33.65%. Growth drivers include rising obesity awareness, healthcare investments, and broader pharmaceutical access.
Key Players
Roche
Roche is a global pharmaceutical company that has recently entered the anti-obesity drugs market. The company has secured licensing agreements for potential weight loss candidates, signaling its interest in expanding its portfolio to include obesity treatments. Roche’s expertise in biotechnology and commitment to addressing unmet medical needs position it as a noteworthy participant in the obesity care landscape.
GlaxoSmithKline (GSK)
GSK is a multinational healthcare company involved in the development of various therapeutic areas, including obesity. The company is exploring the potential of amylin analogs and other hormonal agents for weight management. GSK’s research initiatives aim to provide patients with alternative treatment options and contribute to the advancement of obesity care.
Novo Nordisk
Novo Nordisk is a leading global healthcare company specializing in diabetes and obesity care. The company has developed several GLP-1 receptor agonists, including semaglutide (marketed as Ozempic and Wegovy), which have shown significant efficacy in weight management. Novo Nordisk continues to invest in research and development to expand its portfolio of anti-obesity medications and enhance patient outcomes.
Currax Pharmaceuticals
Currax Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of treatments for obesity. Through strategic acquisitions, such as obtaining rights to Contrave, Currax has expanded its presence in the anti-obesity drugs market. The company’s focus on addressing obesity-related health issues aligns with the growing demand for effective weight management therapies.
Eli Lilly and Company
Eli Lilly is another major player in the anti-obesity drugs market, known for its innovative therapies. The company’s GLP-1 receptor agonist, tirzepatide (marketed as Mounjaro), has demonstrated promising results in clinical trials for weight loss. Eli Lilly’s commitment to obesity care is reflected in its ongoing research efforts and strategic partnerships aimed at advancing treatment options for patients.
Conclusion
The anti‑obesity drugs market is entering a transformative era, with expected growth from USD 25.93 billion in 2025 to USD 100.97 billion by 2030 at a 31.24 % CAGR. This growth is fuelled by the powerful clinical outcomes of GLP‑1 agonists, innovation in oral formulations, expanded access via online pharmacies, and increasing attention to obesity as a chronic disease.
While North America remains the dominant market, Asia‑Pacific’s rapidly growing demand offers substantial opportunities. Competition is intensifying, as established pharmaceutical companies and biotechs alike race to advance next generation therapies and diversify distribution channels.
As market dynamics evolve, stakeholders should monitor:
• Progress of oral GLP‑1 candidates and dual/triple‑agonists like CagriSema
• Regulatory approvals and reimbursement pathways, especially in emerging regions
• Competitive responses from lifecycle extensions to partnerships and acquisitions
• Supply chain robustness and accessibility, particularly amid supply constraints for high‑demand drugs
In sum, the anti‑obesity drugs market is poised for significant expansion, with transformative treatments and shifting delivery models likely to reshape global healthcare delivery and patient outcomes.
For More insights: https://www.mordorintelligence.com/industry-reports/anti-obesity-drugs-market?utm_source=abnewswire
Industry Related Reports
Ozempic Market : The Ozempic Market Report is segmented by region, including North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The report provides both value (in USD) and volume (in units) for each of these segments.
Japan Oral Anti-Diabetic Drug Market: The Japan Oral Anti-Diabetic Drug Market Report is segmented by drug types, including Biguanides, Alpha-Glucosidase Inhibitors, GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, and others, as well as end users, such as Hospitals/Clinics, Personal/Home Care Settings, and others. The report provides market size and forecasts for each segment in terms of value (USD).
Get More Insights: https://www.mordorintelligence.com/industry-reports/japan-oral-anti-diabetic-drug-market?utm_source=abnewswire
Anti-Snoring Market: The Anti-Snoring Devices Market report segments the industry by device type, including Mandibular Advancement Devices (MAD), Tongue Stabilizing Devices (TSD), Continuous Positive Airway Pressure (CPAP) Devices, and other device types. It also segments by surgical procedures such as Uvulopalatopharyngoplasty (UPPP), Somnoplasty, Pillar Procedure, Tonsillectomy, Radiofrequency Palatoplasty, and more. Additionally, the report covers geographical segmentation.
About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
For any inquiries or to access the full report, please contact: [email protected] https://www.mordorintelligence.com/
Media ContactCompany Name: Mordor Intelligence Private LimitedContact Person: Jignesh ThakkarEmail: Send EmailPhone: +1 617-765-2493Address:5th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli City: HyderabadState: Telangana 500008Country: IndiaWebsite: https://www.mordorintelligence.com/
